secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K/A
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001104659-23-088184
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec Q2 revenue $3.3M (+98% QoQ); appoints Adrian Haigh as COO
----------------------------------------------------------------

- Net product revenue $3.3M in Q2 2023, up 98% from $1.7M in Q1 2023.
- Net loss $5.4M ($0.21/share) vs $5.1M ($0.19/share) year ago.
- Adrian Haigh appointed COO, steps down from board; base salary €400K, 200K options.
- Cash $15.0M at June 30, 2023; sufficient for at least 12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465923088184/0001104659-23-088184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465923088184/tm2323025-1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-088184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer